Company Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States.
Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation imipridone ClpP agonist and DRD2 antagonist which is in phase 1 clinical trial to treat central nervous systems and other solid tumors.
The company also develops ONC212, an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP, which is in preclinical trial; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses.
In addition, it offers TEMBEXA, a lipid conjugate which acts via inhibition of viral DNA synthesis that is a medical countermeasure for smallpox.
The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox.
Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2000 |
| IPO Date | Apr 11, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 79 |
| CEO | Michael Andriole |
Contact Details
Address: 2505 Meridian Parkway, Suite 100 Durham, North Carolina 27713 United States | |
| Phone | 919 806 1074 |
| Website | chimerix.com |
Stock Details
| Ticker Symbol | CMRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001117480 |
| CUSIP Number | 16934W106 |
| ISIN Number | US16934W1062 |
| Employer ID | 33-0903395 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael T. Andriole M.B.A. | Chief Executive Officer, President and Director |
| Dr. Michael A. Alrutz J.D., Ph.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Allen S. Melemed M.B.A., M.D. | Chief Medical Officer |
| Michelle LaSpaluto | Chief Financial Officer |
| Thomas J. Riga | Chief Operating and Commercial Officer |
| David Jakeman CPA | Vice President of Accounting and Finance |
| Dr. Roy W. Ware M.B.A., Ph.D. | Chief Manufacturing and Technology Officer |
| Dr. Joshua E. Allen Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | SC 14D9/A | Filing |
| Apr 18, 2025 | SC TO-T/A | Filing |
| Apr 17, 2025 | SCHEDULE 13G | Filing |
| Apr 16, 2025 | 10-K/A | [Amend] Annual report |
| Apr 14, 2025 | SC TO-T/A | Filing |
| Apr 11, 2025 | SC TO-T/A | Filing |
| Apr 10, 2025 | SC TO-T/A | Filing |
| Apr 9, 2025 | SC TO-T/A | Filing |
| Apr 7, 2025 | SC TO-T/A | Filing |
| Apr 7, 2025 | SC 14D9/A | Filing |